Pfizer eyes $7.3bn takeover of weight-loss drug developer Metsera

The deal marks Pfizer's latest bid to secure a foothold in the lucrative anti-obesity drug market
Pfizer eyes $7.3bn takeover of weight-loss drug developer Metsera

Pfizer is closing in on a potential $7.3bn (€6.22bn) takeover of weight-loss drug developer Metsera. Pfizer employs more than 4,000 people in Ireland Picture: Dan Linehan

Pfizer is closing in on a potential $7.3bn (€6.22bn) takeover of weight-loss drug developer Metsera, the Financial Times has reported, citing unidentified sources.

The US pharma firm will acquire New York City-based Metsera for $47.50 per share in cash, with an additional $22.50 per share contingent on the achievement of certain performance milestones, the newspaper said, adding that the announcement could come as early as Monday, unless deal talks fall through.

Already a subscriber? Sign in

You have reached your article limit.

Unlimited access. Half the price.

Annual €120 €60

Best value

Monthly €10€5 / month

More in this section

The Business Hub

Newsletter

News and analysis on business, money and jobs from Munster and beyond by our expert team of business writers.

Cookie Policy Privacy Policy Brand Safety FAQ Help Contact Us Terms and Conditions

© Examiner Echo Group Limited